Author Archives: admin

Top researchers are discussing notable developments in neuroscience, including research in many neuromuscular diseases, at the annual American Academy of Neurology meeting April 21-28.

Best practices for treating amyotrophic lateral sclerosis (ALS) were among the presentations at MDA’s 2012 Clinical Conference, held in March.

Best practices for treating various neuromuscular diseases are described in this third and final report on MDA’s 2012 Clinical Conference.

ALS research news items on findings related to SOD1 in noninherited ALS, toxic SOD1 in ALS-affected tissue, and NIPA1 repeat expansions in ALS.

Increasing levels of heat shock protein 72 reduced signs of Duchenne MD in mouse models of the disease.

Funds will support testing of anti-inflammatory compounds in mice.

In this second report on MDA’s Clinical Conference, updates on experimental therapies in development for six neuromuscular diseases are described.

The Muscular Dystrophy Association announced today that it has extended its strategic research partnership with the nonprofit biotech ALS Therapy Development Institute (ALS TDI) through 2012, with a $2 million grant.

West Virginia University Healthcare has now been designated as an MDA/ALS center by the Muscular Dystrophy Association, in recognition of the high standards of care provided by the team of specialized physicians and therapists for people in West Virgin…

MDA awarded $120,000 to Catabasis Pharmaceuticals to test two anti-inflammatory compounds, CAT-1004 and CAT-1040, in the mdx mouse model of Duchenne MD.